Thursday, March 28, 2024

DCGI approves emergency use of covaxine and covishield

Must Read

The Central Drugs Standard Control Organization (DCGI) on Sunday approved India Biotech’s indigenously used Corona vaccine ‘Kovaxine’ and the emergency use in India of Kovishield manufactured by Pune’s Serum Institute of India (SII). DCGI Dr Venugopal Somani on Sunday briefed the communicators at the National Media Center that the Central Drugs Standard Controller Organization (CDSCO), while accepting the recommendations of the Expert Committee, approved the emergency use of covaxine and covishield. Kovishield is actually developed by Oxford University and pharmaceutical company AstraZeneca and SII has undergone a second and third phase of human trials in India under an agreement as well as producing it here.

The Subject Expert Committee of CDSCO, formed on the use of the Corona vaccine in the country, met on Friday and Saturday. In this meeting, the committee presented its recommendations to the DCGI regarding the emergency use of Kovishield and Kovaxine. The committee also recommended the Phase III human trials of pharmaceutical company Cadila Healthcare. Bharat Biotech has developed Covaxin in collaboration with Indian Council of Medical Research (ICMR). Bharat Biotech on Saturday informed that the number of volunteers involved in the third phase of human trials of covaccine will soon reach its target of 26,000.

Latest News

The wait of the fans is over, the release date of Heeramandi has been announced…

People are eagerly waiting for director Sanjay Leela Bhansali's film 'Heeramandi: The Diamond Bazaar'. #HeeramandiKabReleaseHogi is also trending...